Eonhf, Inc.

36 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Dec 2031

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 11, 2026
The maintenance fee for Neprilysin inhibitors (US 10,315,984) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
1 fee due Jan 2, 2027
The maintenance fee for Neprilysin inhibitors (US 10,336,773) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
3 fees due Feb 4 to 18, 2027 · next Feb 4
2 fees due Mar 1 to 8, 2027 · next Mar 1
1 fee due Apr 6, 2027
The maintenance fee for Neprilysin inhibitors (US 9,150,500) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
1 fee due May 12, 2027
The maintenance fee for Crystalline (2S,4R)-5-(5'-Chloro-2'-Fluoro-[1,1'-Biphenyl]-4-YL)-2-(ETHOXYMETHYL)-4-(3-Hydroxyisoxazole-5-Carboxamido)-2-Methylpentanoic Acid and Uses Thereof (US 10,472,335) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
1 fee due Jun 26, 2027
The maintenance fee for Neprilysin inhibitors (US 11,851,443) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
2 fees due Aug 4 to 25, 2027 · next Aug 4
1 fee due Sep 5, 2027
The maintenance fee for Neprilysin inhibitors (US 11,919,888) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,126,956	Neprilysin Inhibitors In force Term ends Dec 14, 2031 · High confidence	In force	Term ends Dec 14, 2031	High confidence
US 9,388,145	Neprilysin inhibitors In force Ends no later than Dec 14, 2031 · From the USPTO record	In force	Ends no later than Dec 14, 2031	From the USPTO record
US 10,189,823	Neprilysin Inhibitors In force Term ends Dec 14, 2031 · Medium confidence	In force	Term ends Dec 14, 2031	Medium confidence
US 10,336,773	Neprilysin inhibitors In force Term ends Dec 14, 2031 · From the USPTO record	In force	Term ends Dec 14, 2031	From the USPTO record
US 10,759,813	Neprilysin inhibitors In force Term ends Dec 14, 2031 · From the USPTO record	In force	Term ends Dec 14, 2031	From the USPTO record
US 11,851,443	Neprilysin inhibitors In force Term ends Jan 2, 2032 · From the USPTO record	In force	Term ends Jan 2, 2032	From the USPTO record
US 9,108,934	Neprilysin Inhibitors In force Term ends Jan 19, 2032 · High confidence	In force	Term ends Jan 19, 2032	High confidence
US 9,120,747	Neprilysin inhibitors In force Term ends Jan 19, 2032 · From the USPTO record	In force	Term ends Jan 19, 2032	From the USPTO record
US 9,150,500	Neprilysin inhibitors In force Ends no later than Nov 1, 2032 · From the USPTO record	In force	Ends no later than Nov 1, 2032	From the USPTO record
US 10,123,984	Neprilysin inhibitors In force Term ends Nov 1, 2032 · From the USPTO record	In force	Term ends Nov 1, 2032	From the USPTO record

10 of 36 patents shown.

Pro members see all 36.

Pro members: see all 36 patents

Also on record, not counted in the 36: 9 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro